APA
Bruyère O., Cooper C., Arden N., Branco J., Brandi M. L., Herrero-Beaumont G., Berenbaum F., Dennison E., Devogelaer J., Hochberg M., Kanis J., Laslop A., McAlindon T., Reiter S., Richette P., Rizzoli R. & Reginster J. (20160311). Can we identify patients with high risk of osteoarthritis progression who will respond to treatment? A focus on epidemiology and phenotype of osteoarthritis. : Drugs & aging.
Chicago
Bruyère Olivier, Cooper Cyrus, Arden Nigel, Branco Jaime, Brandi Maria Luisa, Herrero-Beaumont Gabriel, Berenbaum Francis, Dennison Elaine, Devogelaer Jean-Pierre, Hochberg Marc, Kanis John, Laslop Andrea, McAlindon Tim, Reiter Susanne, Richette Pascal, Rizzoli René and Reginster Jean-Yves. 20160311. Can we identify patients with high risk of osteoarthritis progression who will respond to treatment? A focus on epidemiology and phenotype of osteoarthritis. : Drugs & aging.
Harvard
Bruyère O., Cooper C., Arden N., Branco J., Brandi M. L., Herrero-Beaumont G., Berenbaum F., Dennison E., Devogelaer J., Hochberg M., Kanis J., Laslop A., McAlindon T., Reiter S., Richette P., Rizzoli R. and Reginster J. (20160311). Can we identify patients with high risk of osteoarthritis progression who will respond to treatment? A focus on epidemiology and phenotype of osteoarthritis. : Drugs & aging.
MLA
Bruyère Olivier, Cooper Cyrus, Arden Nigel, Branco Jaime, Brandi Maria Luisa, Herrero-Beaumont Gabriel, Berenbaum Francis, Dennison Elaine, Devogelaer Jean-Pierre, Hochberg Marc, Kanis John, Laslop Andrea, McAlindon Tim, Reiter Susanne, Richette Pascal, Rizzoli René and Reginster Jean-Yves. Can we identify patients with high risk of osteoarthritis progression who will respond to treatment? A focus on epidemiology and phenotype of osteoarthritis. : Drugs & aging. 20160311.